ReviewJournal of medicinal chemistry2015
Clostridium difficile drug pipeline: challenges in discovery and development of new agents.
Review in Journal of medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.World journal of gastroenterology · 2016Pooled it
- Metronidazole and ether derivatives target Helicobacter pylori via simultaneous stress induction and inhibition.Nature microbiology · 2026Article
- Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides.World journal of microbiology & biotechnology · 2024Review
- Antibiotic Resistances of Clostridioides difficile.Advances in experimental medicine and biology · 2024Article
- Antibiotic Resistances of Clostridioides difficile.Advances in experimental medicine and biology · 2024Article
- A Potent and Narrow-Spectrum Antibacterial againstJournal of medicinal chemistry · 2023Article
- AmidinoquinoxalineRSC advances · 2023Article
- Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid asMolecules (Basel, Switzerland) · 2023Article
- CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.Antimicrobial agents and chemotherapy · 2023Article
- Melatonin as an Antimicrobial Adjuvant and Anti-Inflammatory for the Management of RecurrentAntibiotics (Basel, Switzerland) · 2022Article
- "Omic" Approaches to Bacteria and Antibiotic Resistance Identification.International journal of molecular sciences · 2022Review
- Risk Factors, Diagnosis, and Management ofMicroorganisms · 2022Review
- Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to TargetPharmaceuticals (Basel, Switzerland) · 2022Article
- Frontiers in antibiotic alternatives forWorld journal of gastroenterology · 2021Article
- Review
- Cationic Peptidomimetic Amphiphiles Having aAntibiotics (Basel, Switzerland) · 2021Article
- Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.PLoS computational biology · 2021Article
- Evolution of clinical guidelines for antimicrobial management ofTherapeutic advances in gastroenterology · 2021Review
- Article
- Screening for potent and selective anticlostridial leads among FDA-approved drugs.The Journal of antibiotics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
In the past decade Clostridium difficile has become a bacterial pathogen of global significance. Epidemic strains have spread throughout hospitals, while community acquired infections and other sources ensure a constant inoculation of spores into hospitals. In response to the increasing medical burden, a new C. difficile antibiotic, fidaxomicin, was approved in 2011 for the treatment of C. difficile-associated diarrhea. Rudimentary fecal transplants are also being trialed as effective treatments. Despite these advances, therapies that are more effective against C. difficile spores and less damaging to the resident gastrointestinal microbiome and that reduce recurrent disease are still desperately needed. However, bringing a new treatment for C. difficile infection to market involves particular challenges. This review covers the current drug discovery pipeline, including both small molecule and biologic therapies, and highlights the challenges associated with in vitro and in vivo models of C. difficile infection for drug screening and lead optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.